Synthesis of substituted benzylamino- and heterocyclylmethylamino carbodithioate derivatives of 4-(3H)-quinazolinone and their cytotoxic activity

被引:26
作者
Cao, Sheng-Li [1 ]
Feng, Yu-Ping
Zheng, Xiao-Lin
Jiang, Yu-Yang
Zhang, Me
Wang, Yue
Xu, Meng
机构
[1] Capital Normal Univ, Dept Chem, Beijing 100037, Peoples R China
[2] Tsinghua Univ, Dept Chem, Key Lab Bioorgan Phosphorous Chem & Chem Biol, Beijing 100084, Peoples R China
[3] Tsing Hua Univ, Key Lab Chem Biol, Shenzhen, Peoples R China
关键词
4-(3H)-Qquinazolinone; dithiocarbamate; cytotoxicity; MTT assay;
D O I
10.1002/ardp.200500264
中图分类号
R914 [药物化学];
学科分类号
100701 [药物化学];
摘要
A new series of substituted benzylamino- and heterocyclylmethylamino carbodithioate derivatives of 4-(3H)-quinazolinone were synthesized via four steps starting from 2-amino-5-methylbenzoic acid and initially screened against A-549 (human non-small cell lung cancer), HCT-8 (human colon cancer), and Bel-7402 (human liver cancer) cell lines at the single concentration of 5 mu g/mL using the colorimetric MTT assay. The IC50 values were determined for the compounds reaching >= 70% inhibition in primary screening by serial dilution. Among the newly synthesized compounds, 9n exhibited potent in vitro cytotoxicity against A-549, HCT-8, and Bel-7402 cell lines with the IC50 values of 1.65, 0.93, and 1.43 mu M, respectively.
引用
收藏
页码:250 / 254
页数:5
相关论文
共 16 条
[1]
Synthesis of 5-substituted quinazolinone derivatives and their inhibitory activity in vitro [J].
Baek, DJ ;
Park, YK ;
Heo, HI ;
Lee, MH ;
Yang, ZY ;
Choi, MH .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (23) :3287-3290
[2]
Cao S. L., 2004, HUAXUE SHIJI, V26, P27
[3]
New synthesis of thymidylate synthase inhibitor Raltitrexed [J].
Cao, SL ;
Wan, R ;
Feng, YP .
SYNTHETIC COMMUNICATIONS, 2003, 33 (20) :3519-3526
[4]
Synthesis and in vitro antitumor activity of 4(3H)-quinazolinone derivatives with dithiocarbamate side chains [J].
Cao, SL ;
Feng, YP ;
Jiang, YY ;
Liu, SY ;
Ding, GY ;
Li, RT .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (07) :1915-1917
[5]
Thymidylate synthase inhibitors as anticancer agents: from bench to bedside [J].
Chu, E ;
Callender, MA ;
Farrell, MP ;
Schmitz, JC .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (Suppl 1) :S80-S89
[6]
Creaven PJ, 1998, CANCER CHEMOTH PHARM, V41, P167
[7]
Efficacy, tolerability and management of raltitrexed (Tomudex™) monotherapy in patients with advanced colorectal cancer:: a review of phase II/III trials [J].
Cunningham, D ;
Zalcberg, J ;
Maroun, J ;
James, R ;
Clarke, S ;
Maughan, TS ;
Vincent, M ;
Schulz, J ;
Barón, MG ;
Facchini, T .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (04) :478-486
[8]
Pemetrexed disodium, a novel antifolate with multiple targets [J].
Curtin, N. J. ;
Hughes, A. N. .
LANCET ONCOLOGY, 2001, 2 (05) :298-306
[9]
Novel 2-amino-4-oxo-5-arylthio-substituted-pyrrolo[2,3-d]pyrimidines as nonclassical antifolate inhibitors of thymidylate synthase [J].
Gangjee, A ;
Jain, HD ;
Kisliuk, RL .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (09) :2225-2230
[10]
Non-classical antifolates, 5-(N-phenylpyrrolidin-3-yl)-2,4,6-triaminopyrimidines and 2,4-diamino-6(5H)-oxopyrimidines, synthesis and antitumor studies [J].
Huang, YL ;
Lin, CF ;
Lee, YJ ;
Li, WW ;
Chao, TC ;
Bacherikov, VA ;
Chen, KT ;
Chen, CM ;
Su, TL .
BIOORGANIC & MEDICINAL CHEMISTRY, 2003, 11 (01) :145-157